Compare COMP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COMP | TGTX |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | 3200 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.0B |
| IPO Year | 2021 | 2008 |
| Metric | COMP | TGTX |
|---|---|---|
| Price | $10.02 | $52.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $11.80 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 12.0M | 2.0M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 67.74 | ★ 1746.67 |
| EPS | 0.03 | ★ 0.12 |
| Revenue | ★ $6,961,600,000.00 | $2,785,000.00 |
| Revenue This Year | $90.43 | $49.08 |
| Revenue Next Year | $8.63 | $26.69 |
| P/E Ratio | ★ $332.50 | $436.08 |
| Revenue Growth | ★ 23.67 | N/A |
| 52 Week Low | $5.98 | $25.37 |
| 52 Week High | $13.96 | $54.07 |
| Indicator | COMP | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.80 | 82.82 |
| Support Level | $9.25 | $28.57 |
| Resistance Level | $11.05 | N/A |
| Average True Range (ATR) | 0.56 | 2.43 |
| MACD | 0.19 | 1.13 |
| Stochastic Oscillator | 96.45 | 95.17 |
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.